Johnson & Johnson's Upgraded FullYear Outlook Misses Wall Street Views; Stock Declines
Johnson & Johnson raised its full-year outlook on Tuesday even though the upgraded midpoints missed Wall Street's estimates.
For 2026, the pharmaceuticals giant now expects adjusted per-share...